60 Degrees Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) is a specialty pharmaceutical company focused on developing and commercializing novel therapies for the prevention and treatment of vector-borne and infectious diseases. The company's lead FDA-approved product is ARAKODA (tafenoquine), which was approved in 2018 and is marketed for malaria prophylaxis in individuals aged 18 and older. 60 Degrees Pharmaceuticals is actively working to expand its clinical pipeline by repurposing tafenoquine for other infectious indications, including tick-borne babesiosis, veterinary babesiosis, and respiratory fungal infections. Additionally, the company is developing celgosivir, a host-targeted glucosidase inhibitor, for viral diseases such as dengue fever and Zika.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding commercial outreach for ARAKODA (tafenoquine) in 2026 by doubling the inside sales representative team, launching a point-of-sale savings partnership with GoodRx, and executing an integrated digital 'surround sound' marketing campaign.
Expected impact: Accelerate sales growth, expand prescriber reach, and improve patient affordability and access to malaria prevention.
Advancing clinical trials evaluating tafenoquine for the treatment of babesiosis, including the Phase II B-FREE Chronic Babesiosis Study at Mount Sinai and seasonal patient enrollment for hospitalized babesiosis patients.
Expected impact: Establish the first FDA-approved treatment regimen for chronic and relapsing babesiosis.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides eligible consumers with savings of up to 30% on ARAKODA at over 70,000 pharmacies nationwide, lowering out-of-pocket costs and expanding the brand's retail footprint.
Terms: Enables point-of-sale discounts of up to 30% for eligible self-pay patients.
Integrates ARAKODA into Runway Health's travel medicine platform, allowing international travelers to access physician-led online consultations and home delivery of malaria prophylaxis before departure.
Terms: Commenced April 2, 2026; specific revenue-sharing terms not publicly disclosed.
Grants an exclusive patent license to enable large-scale extraction and purification of castanospermine from Castanospermum australe seeds, supporting the development of Australian Chestnut Extract as a non-prescription botanical supplement.
Terms: Option exercised in January 2026; exclusive licensing terms.